Baseline patient characteristics for new allopurinol users.
| Characteristics | n = 13,341 |
|---|---|
| Followup duration, yrs, mean ± SD | 3.27 ± 1.55 |
| Male, n (%) | 10,410 (78.0) |
| Age, yrs, mean ± SD | 60.2 ± 13.9 |
| BMI, kg/m2, mean ± SD | 31.5 ± 6.6 |
| Race/ethnicity, n (%) | n = 13,341 |
| White | 5469 (41.0) |
| African American | 2089 (15.7) |
| Hispanic | 2608 (19.5) |
| Asian/Pacific Islander | 3086 (23.1) |
| Other | 89 (0.7) |
| Comorbidities, n (%) | |
| Hypertension | 9449 (70.8) |
| Myocardial infarction | 905 (6.8) |
| Congestive heart failure | 1,047 (7.8) |
| Diabetes | 3124 (23.4) |
| Laboratory data | |
| Patients with a baseline eGFR lab level, n (%) | 11,352 (85.1) |
| Baseline eGFR level, ml/min, mean ± SD | 63.5 ± 18.5 |
| CKD stage 1, eGFR ≥ 90 ml/min, n (%) | 1487 (13.1) |
| CKD stage 2, eGFR 60–89 ml/min, n (%) | 5171 (45.6) |
| CKD stage 3, eGFR 30–59 ml/min, n (%) | 4286 (37.8) |
| CKD stage 4, eGFR 15–29 ml/min, n (%) | 426 (3.8) |
| Patients with a baseline SUAa, n (%) | 11,645 (87.3) |
| Baseline SUA, mg/dl, mean ± SD | 8.58 ± 1.8 |
| Concomitant medication use with initial allopurinol | |
| Diuretic use, n (%) | 5212 (39.1) |
| Loop diuretics | 1094 (8.2) |
| Thiazides diuretics | 3750 (28.1) |
| Antiinflammatory medications, n (%)b | |
| NSAID | 4842 (36.3) |
| Corticosteroid | 2816 (21.1) |
| Colchicine | 5073 (38.0) |
| Any of above | 9222 (69.1) |
↵a Serum urate evaluated 12 months prior and up to 30 days after allopurinol dispensing.
↵b Patients could be prescribed more than 2 antiinflammatory medications; antiinflammatory use was extracted from the period covering 30 days prior and up to 30 days after the index allopurinol dispensing. BMI: body mass index; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; SUA: serum urate acid; NSAID: nonsteroidal antiinflammatory drug.